MUM1 and BCL6 but not HGAL are independent prognostic indicators of outcome in nodal diffuse large B-Cell lymphoma

被引：0
|
作者：
Wongchaowart, NT
Segota, E
Pohlman, B
Lossos, IS
Natkunam, Y
Levy, R
Jin, T
Hsi, ED
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Univ Miami, Miami, FL 33152 USA
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
LABORATORY INVESTIGATION | 2006年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1167
引用
收藏
页码：252A / 252A
页数：1
相关论文
共 50 条
  • [41] Arsenic trioxide targets BCL6 oncoprotein for degradation in BCL6-dependent diffuse large B-cell lymphoma
    Yue, Lok Man
    Chau, David Hau Wing
    Piao, Wenying
    Tse, Wai Choi
    Kwong, Yok Lam
    CANCER RESEARCH, 2017, 77
  • [42] Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
    Cerchietti, Leandro
    Melnick, Ari
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 343 - 345
  • [43] A mouse model of diffuse large B-cell lymphoma induced by deregulated BCL6 expression.
    Cattoretti, G
    Pasqualucci, L
    Ballon, G
    Tam, W
    Murty, VV
    Morse, HC
    Dalla-Favera, R
    BLOOD, 2003, 102 (11) : 136A - 136A
  • [44] Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases
    Kim, Do H.
    Medeiros, L. Jeffrey
    Xu, Jie
    Tang, Guilin
    Qiu, Lianqun
    Wang, Sa A.
    Ok, Chi Y.
    Wang, Wei
    Yin, C. Cameron
    You, M. James
    Garces, Sofia
    Lin, Pei
    Li, Shaoying
    MODERN PATHOLOGY, 2025, 38 (05)
  • [45] Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement
    Carreras, Joaquim
    Ikoma, Haruka
    Kikuti, Yara Yukie
    Miyaoka, Masashi
    Hiraiwa, Shinichiro
    Tomita, Sakura
    Kondo, Yusuke
    Ito, Atsushi
    Nagase, Shunsuke
    Miura, Hisanobu
    Kawada, Hiroshi
    Roncador, Giovanna
    Campo, Elias
    Hamoudi, Rifat
    Nakamura, Naoya
    VIRCHOWS ARCHIV, 2024, 484 (04) : 657 - 676
  • [46] Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement
    Joaquim Carreras
    Haruka Ikoma
    Yara Yukie Kikuti
    Masashi Miyaoka
    Shinichiro Hiraiwa
    Sakura Tomita
    Yusuke Kondo
    Atsushi Ito
    Shunsuke Nagase
    Hisanobu Miura
    Hiroshi Kawada
    Giovanna Roncador
    Elias Campo
    Rifat Hamoudi
    Naoya Nakamura
    Virchows Archiv, 2024, 484 : 657 - 676
  • [47] Therapeutic targeting of the BCL6 oncogene in diffuse large B-cell lymphomas
    Melnick, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 97 - 97
  • [48] Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas
    Parekh, Samir
    Prive, Gilbert
    Melnick, Ari
    LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 874 - 882
  • [49] Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma
    Obermann, EC
    Went, P
    Pehrs, AC
    Tzankov, A
    Wild, PJ
    Pileri, S
    Hofstaedter, F
    Dirnhofer, S
    ONCOLOGY REPORTS, 2005, 14 (06) : 1461 - 1467
  • [50] ARSENIC TRIOXIDE TARGETS BCL6 FOR DEGRADATION AND INHIBITS THE PROLIFERATION OF BCL6-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA
    Tse, E.
    Yue, K.
    Chau, D.
    Kwong, Y. -L.
    HAEMATOLOGICA, 2017, 102 : 571 - 571
12345